Table 2.

Univariate and multivariate analyses of PFS and OS

Variable	Category	PFS						OS
		Univariate			Multivariate			Univariate			Multivariate
		HR	95%CI	p value	HR	95%CI	p value	HR	95%CI	p value	HR	95%CI	p value
Gender	Female	0.780	0.418–1.457	0.436				0.945	0.493-1.810	0.865
Age	≥ 60	1.585	0.970–2.590	0.066				1.581	0.936–2.671	0.087
Histology	Non-adenocarcinoma	0.999	0.792–1.262	0.997				0.929	0.726–1.190	0.562
Clinical stage	IV	0.916	0.723–1.160	0.468				0.916	0.710–1.180	0.497
ECOG PS	2	1.503	0.769–2.936	0.233				1.496	0.738–3.036	0.264
Smoking status	Former/Current	1.231	0.977–1.551	0.078				1.240	0.967–1.589	0.090
Line of immunotherapy	≥3	0.957	0.751–1.220	0.722				0.970	0.747–1.261	0.822
Actionable mutations	Undetected/(–)	0.712	0.481–1.055	0.090				0.713	0.480–1.059	0.093
Metastatic sites	≥ 3	1.021	0.810–1.285	0.863				1.008	0.788–1.291	0.947
Adverse events	Yes	1.344	1.051–1.717	0.018	1.011	0.730–1.402	0.945	1.426	1.096–1.855	0.008	0.957	0.675–1.356	0.804
NLR	≥ 5	1.899	1.176–3.067	0.009	1.845	1.002–3.399	0.049	2.311	1.375–3.882	0.002	2.491	1.288–4.819	0.007
PNI	≥ 45	0.512	0.315–0.831	0.007	0.520	0.308–0.877	0.014	0.374	0.222–0.631	<0.001	0.358	0.202–0.636	<0.001
LDH	≥ 240	1.819	1.070–3.093	0.027	1.730	1.010–2.963	0.046	1.997	1.114–3.578	0.020	1.922	1.061–3.481	0.031

PFS progression-free survival, HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, NLR neutrophil-to-lymphocyte ratio, PNI prognostic nutrition index, LDH lactate dehydrogenase

Statistically significant values are in bold (p < 0.05)